

# Michael Schlander

## Curriculum Vitae

### Narrative Overview

Michael Schlander is the founding *Chairman* and *Scientific Director* of the not-for-profit **Institute for Innovation & Valuation in Health Care (InnoVal-HC)**, established in Aschaffenburg and Wiesbaden, Germany, in July 2005.

He has been a full professor (W3, «chair») of **Health Economics** at the **University of Heidelberg**, since 2017. Adhering to the so-called Jülich model, he was granted leave of absence from the University to act as the founding *Head of the Division of Health Economics*, established in January 2017 at the «**German Cancer Research Center**» (DKFZ). In addition, Michael Schlander is an associate professor at the «**Alfred Weber Institute for Economics**» (AWI) of the University of Heidelberg, since July 2020.



Picture © Dierks + Company (Berlin, Parliamentary Evening, November 2025)

The Division of Health Economics at the DKFZ, which had been established newly under the leadership of Otmar D. Wiestler, was closed by Otmar Wiestler's successor when Michael Schlander retired from his role in October 2025 – for strategic reasons at the institutional level, despite an «excellent» international evaluation of the Division in 2023, i.e., only five years after its inauguration.

Before joining the DKFZ in 2017, Michael Schlander served as a full professor for **Health Care & Innovation Management** from 2002 to 2016 at the University of Business and Society *University of Applied Sciences (Hochschule für Wirtschaft und Gesellschaft Ludwigshafen)*.

During the COVID-19 pandemic, he represented the DKFZ on the board of a global **COVID-19 and Cancer Task Force** of the **Union for International Cancer Control** (UICC) under the leadership of Professor Richard Sullivan, King's College London. As of 2021, Professor Schlander has been appointed board member of the **Health Economics Working Group** of the **Organization of European Cancer Institutes** (OECI) under the leadership of Professor Wim van Harten, Netherlands Cancer Institute (NKI), Amsterdam. Under its umbrella, Michael Schlander inaugurated an international **OECI Task Force on Socioeconomic Impact Research** (which he continues to lead), and consensus recommendations for much-needed conceptual and methodological standards in the field were first published in **The Lancet Oncology** in 2024.

Prior to returning to academia in 2002, he had spent 15 years in executive roles (as *Managing Director / CEO; Director of a Strategic Business Unit; Head of Clinical / Euro Development*) in the **international biopharmaceutical industry** with offices in Belgium, Germany, Switzerland, and the United States. The management of the **turn-around** of a medium-sized German pharmaceutical enterprise, the international launches of **pantoprazole** (a proton pump inhibitor for acid-related gastrointestinal disorders), as well as the strategic development of a global **Cancer Business Plan** for one of the top-ten biopharmaceutical companies, and the successful **European clinical development** of new molecules, rank high among the accomplishments during his 15 years in industry.

Further to this, he helped co-found the **German Society for Health Economics** (*Deutsche Gesellschaft für Gesundheitsökonomie*, DGGÖe) in 2008, and in 2012, he acted as the Scientific Chair for the European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Berlin, which had more than 3,500 attendants. He is a member of numerous international scientific associations, including **Health Technology Assessment International** (HTAi), the **International Health Economics Association** (IHEA), and the **Professional Society for Health Economics and Outcomes Research** (ISPOR). In addition to his extensive engagement on peer review boards for a number of medical and economic journals, he is currently serving on the editorial boards of the peer-reviewed journal **Frontiers in Health Services** (with a focus on the sections on Cost and Resource Allocation) and the German language journal for medical ethics (**Zeitschrift für medizinische Ethik**, ZfME).

In 2005, he established a **Health Economics Summer School**, which took place in Heidelberg from 2006 through 2023. Formally under the auspices of the University, the Summer School was later organized by the DKFZ Division of Health Economics in 2019. After an interruption due to the COVID-19 pandemic, the event resumed in February 2023 with a Winter School taking place as previously at the Studio Villa Bosch in Heidelberg.

Following the closure of the venue at Villa Bosch and the strategic decision by the DKFZ management board to discontinue its engagement in health economics, the Heidelberg Health Economics Summer Schools have been taken back to the **Institute of Innovation & Valuation in Health Care (InnoVal-HC)**, and have been moved to new venues in **Bruneck** in South Tyrol in the Italian dolomites (Brunico, Alto Adige, Italia, as of 2024) and in **Wiesbaden** (as of 2026).

As to his academic background, Michael Schlander studied **medicine and psychology** at the University of Frankfurt, and he has been licensed as a physician in Germany since 1985. He received his **M.D. (*summa cum laude*)** from the University of Frankfurt, his Master of Business Administration (**M.B.A., as valedictorian** of the class of 1994) from City University of Seattle, Washington, a **diploma in health economics** from the Stockholm School of Economics (2002), and the ***venia legendi* for health economics** from the University of Heidelberg (2007). Michael Schlander is the recipient of the «Best Contributed Poster Presentation Award» (out of 750 presentations at the 8th Annual European ISPOR Congress in Florence, Italy, in November 2005) and the «ISPOR Distinguished Service Award» for serving as Scientific Program Chair at the 15th Annual European ISPOR Congress in Berlin, Germany, in November 2012. In 2023, he received the Best General Poster Research Presentation Award (out of ~2500 presentations) with Ramon Schaefer [first author] at the Annual European ISPOR Congress, Copenhagen, Denmark, November 2023, who presented their study on the «value of a statistical life year».

For further information, please refer to [www.michaelschlander.com](http://www.michaelschlander.com) and to [www.innoval-hc.com](http://www.innoval-hc.com).

## Michael Schlander

### Overview of Major Projects

(status April 15, 2026)

Michael Schlander has been leading major projects, including but not limited to the following:

- The Value of a Statistical Life Year («VSLY»): Empirical Economic Evidence  
[Health Economics Research]
- The Socioeconomic Impact of Severe Disease from the Perspective of Patients and Their Relatives  
[Socioeconomic Research and Policy]
- Critical Foundations of the «Logic of Cost Effectiveness» and «Cost Effectiveness Thresholds»  
[Health Economics and Policy / HTA / Applied Allocation Ethics]
- The Prediction of Health State Utilities by Multi-Attribute Utility (MAU)-Theory-Based Instruments  
[Health Economics Research and Consulting]
- The Value of Laboratory Medicine in Switzerland  
[Applied Health Economics]
- The Cost of Biopharmaceutical Research and Development (R&D)  
[Applied Health Economics and Strategic Management]
- European Consensus on the Valuation of Treatments for Ultra-Rare Diseases (URDs)  
[Applied Health Economics and Consulting]
- «SwissHTA» – a Multistakeholder Consensus on Health Technology Assessment in Switzerland  
[Applied Health Economics / HTA and Consulting]
- Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE)  
[Applied Health Economics / HTA]
- The Pharmacoeconomics of Drug Treatment in Child & Adolescent Psychiatry  
[Applied Health Economics / HTA and Consulting]
- The «Nordbaden Project» – Epidemiology, Health Care Utilization, and Costs of ADHD in Germany  
[Pharmacoepidemiology and Applied Health Economics]
- «Cancer Business Plan» for one of the global Top-Ten Biopharmaceutical Corporations  
[Strategic Management]
- The Contribution of Health Economics to Market-Oriented Pharmaceutical Research & Development  
[Strategic Management and Consulting]
- Global and National Launch and Post-Launch Development of Pantoprazole  
[Strategic and Operational Management]

## Michael Schlander

### Publication Overview

(status April 15, 2026)

Michael Schlander has authored >>500 scientific publications in journals and at congresses with *external peer-review*, including but not limited to the following:

#### M. Schlander:

Financing Health Care: Structural Challenges. [German]

***Zeitschrift für medizinische Ethik (ZfmE)*** 2026: 72, 20-46.

#### J.N.A. Tetteh, M. Schlander:

Exploring the Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI3, 15D, AQoL4D and AQoL8D Multiattribute Utility Instruments to SF-36 Dimensions.

***PharmacoEconomics Open*** 2026 (<https://doi.org/10.1007/s41669-026-00645-y>), 1-16.

M.-W. Lwin, O. Schoffer, C. Streissnig, P. Wimberger, M. Gerken, V. Bierbaum, C. Bobeth, M. Roessler, P. Droege, T.Z. Ruhnke, C. Guenster, K. Kleihues-van Tol, T. Link, A. Scharf, E.C. Sturm-Inwald, K. Kast, T. Papatthemelis, O. Ortman, M. Klinkhammer-Schalke, J. Schmitt, M. Schlander:

A Cost-Effectiveness Analysis of Breast Cancer Treatment in Certified vs Non-Certified Hospitals in Germany.

***International Journal of Cancer*** 2026 (DOI: 10.1002/ijc.70388), 1-14.

J. Ubels, J. Vancoppenolle, J. Tetteh, W.H. van Harten, V. Retèl, M. Schlander, N. Franzen

Towards a validated European instrument to measure the socioeconomic impact of cancer.

***International Journal of Cancer*** 2026 (DOI: 10.1002/ijc.70364), 1-12.

#### S. Holm, M. Schlander:

Population health impact of NICE-recommended new drugs.

***The Lancet*** 2025: 405 (10497) 2276.

J. Vancoppenolle, N. Franzen, L. Azarang, T. Juslin, M. Krini, T. Lubbers, J. Mattson, D. Mayeur, R. Menezes, J. Schmitt, F. Scotte, O. Seoane López, T. Skaali, J. Ubels, M. Schlander, V. Retel, W.H. van Harten; OEI Working Group Health Economics:

Financial toxicity and socioeconomic impact of cancer in Europe.

***ESMO Open*** 2025: 10 (6): 105293.

D. Doege, J. Frick, R.D. Eckford, L. Koch-Gallenkamp, M. Schlander; Baden-Wuerttemberg Cancer Registry; V. Arndt:

Anxiety and depression in cancer patients and survivors in the context of restrictions in contact and oncological care during the COVID-19 pandemic.

***International Journal of Cancer*** 2025: 156 (4) 711-722.

*P.D. Pham, J. Ubels, R.D. Eckford, M. Schlander:*

Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments.

***Pharmacoeconomics Open*** 2025: 9 (4) 519-539.

*M.T. Muchadeyi, S. Hao, K. Hernandez-Villafuerte, S.A. Khan, N. Becker, A. Krilaviciute, P. Seibold, R. Gulati, P. Albers, M. Schlander, M. Clements:*

Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.

***International Journal of Cancer*** 2025: 157 (8) 1662-1679.

*M. Schlander:*

Health economics and resource allocation at the end of life.

***Zeitschrift für medizinische Ethik (ZfmE)*** 2024: 70, 303–326.

*M. Schlander, W.H. van Harten, V.P. Retèl, P.D. Pham, J.M. Vancoppenolle, J. Ubels, O.S. López, C. Quirland, F. Maza, E. Aas, B. Crusius, A. Escobedo, N. Franzen, J. Fuentes-Cid, D. Hernandez, K. Hernandez-Villafuerte, I. Kirac, A. Paty, T. Philip, S. Smeland, R. Sullivan, E. Vanni, S. Varga, T. Vermeulin, R.D. Eckford:*

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

***The Lancet Oncology*** 2024: 25 (4) e152-e163.

*M.W. Lwin, C.-Y. Cheng, S., Calderazzo, C. Schramm, M. Schlander:*

Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.

***Frontiers in Public Health*** 2024: 12: 1307427.

*V. Zaika, M.K. Prakash, C.-Y. Cheng, M. Schlander, B.M. Lang, N. Beerenwinkel, A. Sonnenberg, N. Krupka, B. Misselwitz, J. Poleszczuk:*

Optimal timing of a colonoscopy screening schedule depends on adenoma detection, adenoma risk, adherence to screening and the screening objective: A microsimulation study.

***PLoS One*** 2024: 19 (5) :e0304374. doi: 10.1371/journal.pone.0304374.

*J. Ubels, K. Hernandez-Villafuerte, E. Niebauer, M. Schlander:*

The Use of a Comprehensive Concept of Capability for Wellbeing Assessment: A Best-Fit Framework Synthesis.

***Health Care Analysis*** 2024: doi: 10.1007/s10728-024-00488-w. Published online August 24, 2024.

*M.T. Muchadeyi, K. Hernandez-Villafuerte, G.L. Di Tanna, R.D. Eckford, Y. Feng, M. Meregaglia, T. Peasgood, S. Petrou, J. Ubels, M. Schlander:*

Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations.

***Pharmacoeconomics*** 2024: 42 (7) 767-782.

*J. Ubels, M. Schlander:*

Measurement invariance and adapted preferences: evidence for the ICECAP-A and WeRFree instruments.

***Health and Quality of Life Outcomes*** 2023; 21 (1): 121, 1-11. doi: 10.1186/s12955-023-02208-9

*R. Schaefer, D. Hernández, T. Baernighausen, P. Kolominsky-Rabas, M. Schlander:*

Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.

***Value in Health*** 2023; 26 (7): 1032-1044.

*P.D. Pham, M. Schlander, R. Eckford, K. Hernandez-Villafuerte, J. Ubels:*

Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients: A 'Best-Fit' Framework Synthesis.

***The Patient*** 2023; 16 (5): 515-536.

*C.Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander:*

Modeling the Natural History and Screening Effects of Colorectal Cancer Using Both Adenoma and Serrated Neoplasia Pathways: The Development, Calibration, and Validation of a Discrete Event Simulation Model.

***MDM Policy & Practice*** 2023; 8 (1): 23814683221145701. doi: 10.1177/23814683221145701.

*S.A. Khan, K. Hernandez-Villafuerte, D. Hernandez, M. Schlander:*

Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.

***Frontiers in Public Health*** 2023; 10:946544. doi: 10.3389/fpubh.2022.946544.

*J. Schneider J, D. Hernandez D; CAESAR study group; M. Schlander, V. Arndt:*

Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: a multi-regional population-based study.

***Journal of Cancer Survivorship*** 2023; 17 (6) 1639-1659.

*D. Hernandez, F. Wagner F, K. Hernandez-Villafuerte, M. Schlander:*

Economic Burden of Pancreatic Cancer in Europe: a Literature Review.

***Journal of Gastrointestinal Cancer*** 2023; 54 (2) 391-407.

*D. Hernandez, C.Y. Cheng, K. Hernandez-Villafuerte, M. Schlander:*

Survival and comorbidities in lung cancer patients: Evidence from administrative claims data in Germany.

***Oncology Research*** 2023; 30 (4) 173-185.

*M.S.Y. Thong, D. Doege, L. Weißer, L. Koch-Gallenkamp, H. Bertram, A. Eberle, B. Holleczeck, A. Nennecke, A. Waldmann, S.R. Zeissig, R. Pritzkeleit, M. Schlander, H. Brenner, V. Arndt:*

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study.

***Journal of Cancer Research and Clinical Oncology*** 2022; 148 (1) 155-162.

*V. Arndt, D. Hernandez, M. Schlander:*

Income loss after cancer – Results from Germany.

***Onkologie*** 2022: 28 (11) 951–956

*M. Schlander, J. Richardson:*

QALYs In Health Resource Usage Decisions.

***Health Affairs (Millwood)*** 2022: 41 (4) 609-610.

*M. Brougham, M. Schlander, H. Telser, S. Bakshi, O. Sola-Morales:*

Use of the incremental cost-effectiveness ratio for decision-making policies-what is the problem? A perspective paper.

***Expert Review of Pharmacoeconomics & Outcomes Research*** 2022: 22 (6): 913-918.

*R.D. Eckford, A. Gaisser, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E. C. Winkler, S. Weg-Remers, M. Schlander:*

The COVID-19 pandemic and cancer patients in Germany: impact on treatment, follow-up and psychological burden.

***Frontiers in Public Health*** 2022: Feb 9;9:788598. doi: 10.3389/fpubh.2021.788598.

*D. Moro, M. Schlander, H. Telser, O. Sola-Morales, M.D. Clark, A. Olaye, C. Camp, M. Jain, T. Butt, S. Bakshi:*

Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].

***Expert Review of Pharmacoeconomics & Outcomes Research*** 2022: 22 (4) 581-598.

*J. Ubels, K. Hernandez-Villafuerte, M. Schlander:*

The Value of Freedom: A Review of the Current Developments and Conceptual Issues in the Measurement of Capability.

***Journal of Human Development and Capabilities*** (2022) 23 (3) 327–353.

*A. Gaisser, R.D. Eckford, V. Arndt, D. Doege, E. Kludt, J. Ubels, M. Schlander, S. Weg-Remers:*

Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer.

***Onkologie (Berlin)*** 2022: 28 (3): 248-252.

*T.M. Muchandifunga, K. Hernandez-Villafuerte, M. Schlander:*

Quality appraisal for systematic literature reviews of health state utility values. A descriptive analysis.

***BMC Medical Research Methodology*** (2022) 22 (1): 303. doi: 10.1186/s12874-022-01784-6.

*J.W. März, A. Molnar, S. Holm, M. Schlander:*

The Ethics of COVID-19 Vaccine Allocation: Don't Forget the Trade-Offs!

***Public Health Ethics*** 2022: 15 (1) 41-50.

*J.W. März, M. Schlander:*

Not kennt kein Gebot? Die *Rule of Rescue* als Leitprinzip in der Covid-19-Pandemie.

***AMOS International*** 2021: 15 (3) 39-44.

M. Schlander, K. Hernandez-Villafuerte, C-Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:

How much does it cost to research and develop a new drug? A systematic review and assessment.

**Pharmacoeconomics** 2021: 39 (11) 1243-1269.

C.Y. Cheng, T. Datzmann, D. Hernandez, J. Schmitt, M. Schlander:

Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.

**International Journal of Cancer** 2021: 149 (10): 1744-1754.

A. Deibel, L. Deng, C.Y. Cheng, M. Schlander, T. Ran, B. Lang, N. Krupka, N. Beerenwinkel, G. Rogler, R. Wiest, A. Sonnenberg, J. Poleszczuk, B. Misselwitz:

Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach.

**Gastrointestinal Endoscopy** 2021: 94 (2) 379-390. e7.

J. W. März, S. Holm, M. Schlander:

Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?

**Medicine, Health Care and Philosophy** 2021: 24 (4) 487-492.

D. Hernandez, M. Schlander:

Income loss after a cancer diagnosis in Germany: An analysis based on the socio-economic panel survey.

**Cancer Medicine** 2021: 10 (11): 3726-3740.

M. Schlander:

HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".

**International Journal of Health Policy and Management** 2021: 10 (3) 158-161.

R. Schaefer, D. Hernandez, L. Selberg, M. Schlander:

Health Technology Assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?

**Journal of Comparative Effectiveness Research** 2021: 10 (16): 1187-1195.

S.A. Khan, K.V. Hernandez-Villafuerte, M.T. Muchadeyi, M. Schlander:

Cost-effectiveness of risk-based breast cancer screening: A systematic review.

**International Journal of Cancer** 2021: doi: 10.1002/ijc.33593.

M. Schlander:

Patient-reported outcomes (PRO) and quality of life in oncology.

**Forum** 2020: 35, 382-390.

T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:

Cost of decentralized CAR T-cell production in an academic nonprofit setting.

**International Journal of Cancer** 2020: 147 (12): 3438–3445.

*J.M. Heard, C. Vrinten, M. Schlander, C.M. Bellettato C. van Lingen, M. Scarpa; MetabERN Collaboration Group:*

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.

***Orphanet Journal of Rare Diseases*** 2020: 15 (1): 3. doi: 10.1186/s13023-019-1280-5.

*J. Richardson, M. Schlander:*

Health Technology Assessment (HTA) and economic evaluation: efficiency or fairness first.

***Journal of Market Access & Health Policy*** 2019: 7(1) 1-12.

*J.J. Caro, J.E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:*

Determining value in Health Technology Assessment: Stay the course or tack away?

***Pharmacoeconomics*** 2019: 37 (3) 293-299.

*T. Ran, C.-Y. Cheng, B. Misselwitz, H. Brenner, J. Ubels, M. Schlander:*

Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review.

***Clinical Gastroenterology and Hepatology*** 2019: 17 (10): 1969-1981. e15.

*M. Wagner, D. Samaha, R. Casciano, M. Brougham, P. Abrishami, C. Petrie, B. Avouac, L. Mantovani, A. Sarría-Santamera, P. Kind, M. Schlander, M. Tringali:*

Moving Towards Accountability for Reasonableness - A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study.

***International Journal of Health Policy and Management*** 2019: 8 (7):424-443.

*R. Schaefer, M. Schlander:*

Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?

***Expert Review of Pharmacoeconomics & Outcomes Research*** 2019: 19 (4): 453-462.

*V. Jantzer, M. Schlander, J. Haffner, P. Parzer, S. Trick, F. Resch, M. Kaess:*

The cost incurred by victims of bullying from a societal perspective: estimates based on a German online survey of adolescents.

***European Child + Adolescent Psychiatry*** 2019: 28 (4): 585-594.

*J. Espin, M. Schlander, B. Godman, P. Anderson, J. Mestre-Ferrandiz, I. Borget, A. Hutchings, S. Flostrand, A. Parnaby, C. Jommi C:*

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

***Applied Health Economics and Health Policy*** 2018: 16 (6): 803-817.

*M. Schlander, C.M. Dintsios, A. Gandjour:*

Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.

***Value in Health*** 2018: 21 (5): 525-531.

*M.-J. Linton, P.M. Mitchell, H. Al-Janabi, M. Schlander, J. Richardson, A. Iezzi, J. Ubels, J. Coast:*  
Comparing the German Translation of the ICECAP-A Capability Wellbeing Measure to the Original English Version: Psychometric Properties across Healthy Samples and Seven Health Condition Groups.  
***Applied Research in Quality of Life*** 2018: 15 (5). doi 10.1007/s11482-018-9681-5

*M. Schlander, C.Y. Cheng, T. Ran:*

The health economics of cancer screening in Germany: Which population-based interventions are cost-effective?

***Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz*** 2018: 61 (12): 1559-1568.

*L. Annemans, S. Aymé, Y. Le Cam, K. Facey, P. Gunther, E. Nicod, M. Reni, J.L. Roux, M. Schlander, D. Taylor, C. Tomino, J. Torrent-Farnell, S. Upadhyaya, A. Hutchings, L. Le Dez:*

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).

***Orphanet Journal of Rare Diseases*** 2017: 12( 1) 50. doi: 10.1186/s13023-017-0601-9.

*M. Schlander:*

Woran bemisst sich Effizienz im Gesundheitswesen? Zur Klärung fachwissenschaftlicher Begriffe und Kriterien.

***Amos International*** 2017: 11 (1) 22-31.

*M. Schlander, S. Garattini, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà-Morales, K. Tolley, M. Toumi:*

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.

***Journal of Market Access & Health Policy*** 2016: 4. doi: 10.3402/jmahp.v4.33039.

*M. Schlander:*

Conventional Health Economic Evaluation Fails to Capture Social Value of Interventions for Rare and Ultra-Rare Disorders.

***Drug Information Association (DIA) Global Forum*** October 2016: 13-14.

*A. Philipsen, T. Jans, E. Graf, S. Matthies, P. Borel, M. Colla, L. Gentschow, D. Langner, C. Jacob, S. Gross-Lesch, E. Sobanski, B. Alm, M. Schumacher-Stien, M. Roesler, W. Retz, P. Retz-Junginger, B. Kis, M. Abdel-Hamid, V. Heinrich, M. Huss, C. Kornmann, A. Bürger, E. Perlov, G. Ihorst, M. Schlander, M. Berger, L. Tebartz van Elst; Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium:*

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

***JAMA Psychiatry*** 2015: 72 (12): 1199-1210.

*M. Schlander, C.C. Adarkwah, A. Gandjour:*

Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.

***Expert Review of Pharmacoeconomics and Outcomes Research*** 2015: 15 (1): 171-179.

M. Schlander, S. Garattini, S. Holm, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.

***Journal of Comparative Effectiveness Research*** 2014: 3 (4) 399-422.

A. Gandjour, A. Gafni, M. Schlander:

Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.

***Expert Review of Pharmacoeconomics and Outcomes Research*** 2014: 14 (1): 123-129.

M. Schlander, S. Garattini, S. Holm, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, M. Toumi:

How (Not) To Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs): Recommendations from the URD Evaluation Project.

***ISPOR Connections*** 2014: 20 (6) 15-17.

M. Schlander, A. Jaecker, M. Voelkl:

Arzneimittelpreisregulierung nach den Prinzipien der Sozialen Marktwirtschaft.

Part 1: ***Die Pharmazeutische Industrie [PharmInd]*** 2013: 75 (3) 384-389.

Part 2: ***Die Pharmazeutische Industrie [PharmInd]*** 2013: 75 (4) 589-584.

M. Schlander, A. Jaecker, M. Voelkl:

Arzneimittelpreise: Preisbildung in einem besonderen Markt.

***Deutsches Arzteblatt*** 2012: 109 (11) A524-528.

M. Schlander:

Why Do Health Economists Complain that Health Politicians Don't Listen to Them? A Perspective from Germany.

***ISPOR Connections*** 2012: 18 (6) 14.

M. Schlander, O. Schwarz, A. Rothenberger, V. Roessner:

Tic disorders: administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample.

***European Psychiatry*** 2011: 26 (6) :370-374.

T. Reinhold, B. Brüggjenjürgen, M. Schlander, S. Rosenfeld, F. Hessel, S.N. Willich:

Economic analysis based on multinational studies: methods for adapting findings to national contexts.

***Journal of Public Health*** 2010: 18 (4) 327-335.

A. Philipsen, E. Graf, L. Tebartz van Elst, T. Jans, A. Warnke, B. Hesslinger, D. Ebert, M. Gerlach, S. Matthies, M. Colla, C. Jacob, E. Sobanski, B. Alm, M. Rösler, G. Ihorst, S. Gross-Lesch, L. Gentschow, B. Kis, M. Huss, K. Lieb, M. Schlander, M. Berger:

Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial.

***Attention Deficit Hyperactivity Disorders*** 2010: 2 (4): 203-212.

M. Schlander:

The pharmaceutical economics of child psychiatric drug treatment.

**Current Pharmaceutical Design** 2010: 16 (22): 2443-2461

M. Schlander, G.E. Trott, O. Schwarz:

The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness.

**Nervenarzt** 2010: 81 (3): 289-300.

M. Schlander, G.E. Trott, O. Schwarz:

The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness.

**Nervenarzt** 2010: 81 (3): 301-314.

M. Schlander:

Measures of efficiency in healthcare: QALMs about QALYs?

**Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen** 2010: 104 (3): 214-226.

M. Schlander:

Health economics: in search of efficiency.

**Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen** 2009: 103 (2): 117-125.

M. Schlander:

Reference Case.

In: M. Kattan (ed.): **Encyclopedia of Medical Decision-Making**.

Thousand Oaks, CA: Sage 2009.

M. Schlander, M. Beck:

Expensive Drugs for Rare Disorders: To Treat or Not to Treat? The Case of Enzyme Replacement Therapy for Mucopolysaccharidosis VI.

**Current Medical Research and Opinion** 2009: 25 (9) 1285-1293.

M. Schlander:

The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): No(t yet) an exemplar of a deliberative process.

**Journal of Medical Ethics (JME)** 2008: 34 (7) 534-539.

[Paper selected by JME as "Editor's Choice" of the Month]

M. Schlander:

Has NICE got it right? An international perspective.

**Current Medical Research and Opinion** 2008: 24 (4) 951-966.

M. Schlander:

Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).

**Current Medical Research and Opinion** 2008: 24 (2): 515-535.

M. Schlander:

The NICE ADHD health technology assessment: a review and critique.

**Child and Adolescent Psychiatry and Mental Health** 2008; 2 (1): 1. doi: 10.1186/1753-2000-2-1.

M. Schlander:

The luck of being late: Should international health care policy makers follow the NICE model?

**Journal of Medical Economics** 2008; (1) 1-2.

M. Schlander:

Aktuelle Daten zur medizinischen Versorgung von Kindern und Jugendlichen mit ADHS in Deutschland: Administrative Prävalenz, beteiligte Arztgruppen und Arzneimitteltherapie.

**psychoneuro** 2007; 33 (10) 412-415.

G.E. Trott, M. Schlander:

Children with attention deficit hyperactivity disorder in school.

**MMW Fortschritte der Medizin** 2007; 149 (47): 32-35.

M. Schlander:

Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

**European Child + Adolescent Psychiatry** 2007; 16 (7): 421-429.

E.M., Foster, P.S. Jensen, M. Schlander, W.E. Pelham Jr., L. Hechtman, L.E. Arnold, J.M. Swanson, T. Wigal:

Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

**Health Services Research** 2007; 42 (1 Pt. 1) 165-182.

M. Schlander:

NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).

**Current Medical Research and Opinion** 2007; 23 (1): 207-222.

M. Schlander:

Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence.

**Child and Adolescent Psychiatry and Mental Health** 2007; 1 (1): 13. doi: 10.1186/1753-2000-1-13.

M. Schlander, O. Schwarz, G.E. Trott, M. Viapiano, N. Bonauer:

Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision.

**European Child + Adolescent Psychiatry** 2007; 16 (7): 430-438.

P.S. Jensen, J.A. Garcia, S. Glied, M. Crowe, M. Foster, M. Schlander, S. Hinshaw, B. Vitiello, L.E. Arnold, G. Elliott, L. Hechtman, J.H. Newcorn, W.E. Pelham, J. Swanson, K. Wells:

Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.

**American Journal of Psychiatry** 2005; 162 (9) 1628-1936.

M. Schlander:

Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsökonomie?

In: H.A. Kick, J. Taupitz (editors), **Gesundheitswesen zwischen Wirtschaftlichkeit und Menschlichkeit**. LIT-Verlag, Münster, 2005: 37-112.

M. Schlander:

Drug utilization and pharmaceutical cost-containment in Germany-perspectives 1 year after enactment of the GMG.

**Medizinische Klinik (Munich)** 2005: 100 (6): 314-324.

M. Schlander, O. Schwarz:

Affordability of Increasing Health Care Expenditures in Germany: A Macroeconomic Analysis.

**Gesundheitsoekonomie & Qualitätsmanagement** 2005: 10 (3) 178-187.

M. Schlander, C. Thielscher, O. Schwarz:

Affordability sensitive to economic growth rates.

**Health Affairs (Millwood)** 2004: 23 (1) 276-267.

M. Stadler, M. Schlander, M. Braeckman, T. Nguyen, J.G. Boogaerts:

A cost-utility and cost-effectiveness analysis of an acute pain service.

**Journal of Clinical Anesthesia** 2004: 16 (3) 159-167.

M. Schlander, O. Schwarz, C. Thielscher:

Health Care Expenditures in Germany: A Macroeconomic Analysis of Long-Term Affordability (Ability-to-Pay).

In: B. Kremin-Buch, F. Unger, H. Walz, E. Häusler (eds.): **Gesundheitsökonomie - Eine Langfristorientierung**.

Sternenfels: Verlag Wissenschaft & Praxis Dr. Brauner 2004, 83-129.

M. Schlander:

Vor der Ökonomisierung der ADHS-Therapie? Gesundheitsökonomische Aspekte.

In: T. Fitzner, W. Stark (eds.) **Doch unzerstörbar ist mein Wesen... Diagnose AD(H)S - Schicksal oder Chance?**

Weinheim: Beltz-Verlag 2004, 417-466.

M. Schlander:

Zur Logik der Kosten-Effektivität: Gesundheitsökonomie und Ressourcenallokation.

**Deutsches Ärzteblatt** 2003: 100 (33) A2140-A2141.

F. Gantner, C. Schweiger, M. Schlander:

Naming, Classification, and Trademark Selection: Implications for Market Success of Pharmaceutical Products.

**Drug Information Journal** 2002: 36, 807-824.

M. Schlander:

Rationing Health Care? Rational Resource Allocation in the Health Care System:

Part 1: Why Rationing will become Inevitable.

Part 2: Spending Decisions by Patients.

Part 3: Spending Decisions by Third Parties.

Part 4: Spending Decisions by Physicians.

**Medizinische Welt** 1999: 50, 210-216, 140-147, 83-90, and 36-41.

M. Schlander:

Health Economics: Integrating a New Functional Area into the Pharmaceutical Corporation.

In: W. Braun, R. Schaltenbrand (eds.): **Die Nutzung der Ressource Synergie - Zukunftssicherung für Forschung, Marketing und Vertrieb.**

Witten: Universität Witten-Herdecke Verlagsgesellschaft 1998, 150-170.

M. Schlander:

Möglichkeiten und Grenzen der Patientenselbstbeteiligung: Wirtschaftliche und medizinisch-ethische Aspekte der Selbstbeteiligung von Patienten an den Kosten des Gesundheitssystems.

In: W. Braun, R. Schaltenbrand (eds.): **Gesundheitswesen 2010: Prognosen, Trends und Chancen.**

Witten: Universität Witten-Herdecke Verlagsgesellschaft 1998, pp. 82-103.

*K. Herfarth, S. Drechsler, W. Imhoff, M. Schlander, M. Engelbach, A. Maier, H. Schmidt-Gayk:*

Calcium regulating hormones after oral and intravenous calcium administration.

**European Journal of Clinical Chemistry and Clinical Biochemistry** 1992: 30 (12) 815-822.

*H. Schrezenmeier, M. Schlander, A. Raghavachar:*

Cyclosporin A in aplastic anemia--report of a workshop.

**Annals of Hematology** 1992: 65 (1): 33-36.

*R. Handgretinger, T. Klingebiel, R. Dopfer, R. Siedner, B. Baden, S. Wendt, H.G. Scheel-Walter, P. Scheel, M. Schlander, D. Niethammer:*

Peripheral stem cell collection and transplantation in pediatric patients.

**Progress in Clinical and Biological Research** 1992: 377, 615-620.

*M. Schlander, S. Hoyer, M. Frotscher:*

Glutamate decarboxylase-immunoreactive neurons in the aging rat hippocampus are more resistant to ischemia than CA1 pyramidal cells.

**Neuroscience Letters** 1988: 91 (3)241-246.

*M. Schlander, G. Thomalske, M. Frotscher:*

Fine structure of GABAergic neurons and synapses in the human dentate gyrus.

**Brain Research** 1987: 401 (1): 185-189.

*M. Frotscher, M. Schlander, C. Léránth:*

Cholinergic neurons in the hippocampus. A combined light- and electron-microscopic immunocytochemical study in the rat.

**Cell and Tissue Research** 1986: 246 (2) 293-301.

M. Schlander, M. Frotscher:

Non-pyramidal neurons in the guinea pig hippocampus. A combined Golgi-electron microscope study.  
***Anatomy and Embryology (Berlin)*** 1986: 174 (1) 35-47.

### **Books and Monographs**

M. Schlander, L. Selberg, R. Schaefer:

***Nutzen der Labormedizin in der Schweiz.***  
Springer Nature, Heidelberg 2023

M. Schlander:

***Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE): A Qualitative Study.***

Springer, New York, NY, 2007.

M. Schlander:

***The Contribution of Health Economics to Market-Oriented Pharmaceutical Research and Development.***  
Universität Witten-Herdecke Verlagsgesellschaft, Witten 1998.

M. Schlander, D. Schäfer (editors):

***Zwei Jahre Gesprächskreis Immunologie Sandoz AG, Nürnberg, 1989-1991.*** With contributions by M. Freund, H. Gerhartz, C. Huber, T. Jones, R. Kroczeck, J. Mason, C. Peschel, A. Raghavachar, D. Schiwiek, M. Schlander, and H. Schrezenmeier.  
Sandoz AG, Nuremberg (Germany) 1991.